0001062993-24-002322.txt : 20240207
0001062993-24-002322.hdr.sgml : 20240207
20240207173516
ACCESSION NUMBER: 0001062993-24-002322
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240207
FILED AS OF DATE: 20240207
DATE AS OF CHANGE: 20240207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GILEAD SCIENCES, INC.
CENTRAL INDEX KEY: 0000882095
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41947
FILM NUMBER: 24606014
BUSINESS ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 6505743000
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
FORMER NAME:
FORMER CONFORMED NAME: GILEAD SCIENCES INC
DATE OF NAME CHANGE: 19930328
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kyverna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001994702
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831365441
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5980 HORTON STREET
STREET 2: SUITE 550
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5106268331
MAIL ADDRESS:
STREET 1: 5980 HORTON STREET
STREET 2: SUITE 550
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
3
1
form3.xml
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
X0206
3
2024-02-07
0
0001994702
Kyverna Therapeutics, Inc.
KYTX
0000882095
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY
CA
94404
0
0
1
0
Series A-2 Convertible Preferred Stock
Common Stock
1514083
D
Series B Convertible Preferred Stock
Common Stock
1702036
D
The convertible preferred stock is convertible at any time, at the holder's election, on a one-for-one basis, and will convert automatically upon the issuer's consummation of an initial public offering. The preferred stock has no expiration date.
Reflects a 1-for-4.5511 reverse stock split of the issuer's common stock, effected on January 30, 2024.
Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
2024-02-07